Pulmeze is developing a new treatment for the symptoms of Cystic Fibrosis and other respiratory ailments. Pulmeze harnesses the power of the Inhalyte™ solution to allow for unprecedented relief from respiratory infections. Inhalyte uses proven technology in a new way to provide a relief from mucus build up combined with a dramatic reduction in infection causing bacteria.
What sets Inhalyte™ apart?
Inhalyte™ uses no antibiotics,
only salt and water.
Inhalyte™ utilises electrochemical activation (ECA) to produce an active solution that has vastly improved bactericidal properties. This solution has proved to be very safe for human contact and has been FDA approved for use in food preparation.
Inhalyte™ is effective against a wide range of antibiotic resistant and gram-negative bacteria. Early trials have shown very positive results as a treatment for Cystic Fibrosis. It is intended that following Clinical Trials the treatment will be expanded to other conditions including Sinusitis, Ventilator Acquired Pneumonia, Asthma, Chronic Bronchitis and Aspergillosis.
Crucially, because Inhalyte does not use antibiotics it presents an unprecedented opportunity to develop new and more sensitive treatments for conditions at risk from antibiotic resistance.
Pulmeze is currently designing Phase I and Phase II clinical trials.
For more information on the Pulmeze project please contact us on firstname.lastname@example.org
Copyright © 2012 Pulmeze Limited